
Aihua Fu is a nanobiotechnologist and the co-founder, President and CEO of NVIGEN Inc., a San Jose nanobiotechnology company building molecularly engineered magnetic and fluorescent nanoparticles for cancer detection and personalized medicine. Trained as a chemist under Nobel-track nanoscience pioneer A. Paul Alivisatos at UC Berkeley and as a postdoc at Stanford, she turned quantum-dot and magnetic-bead research into commercial tools for liquid biopsy, cfDNA extraction, single-cell sequencing and circulating tumor cell capture. Her flagship NVIGEN X and NERNST-Seq platforms aim to read DNA, RNA, protein and cell signals together to predict cancer recurrence early and guide therapy.
NVIGEN Inc. is a Sunnyvale, California nanobiotechnology company that engineers multifunctional, biodegradable magnetic and fluorescent nanoparticles for biomedical research, diagnostics and therapeutics. Built on its proprietary nanoparticle-imaging-delivery (NID) and MagVigen platforms, NVIGEN makes reagents and assays that capture DNA, RNA, proteins and rare cells from a single blood or tissue sample - powering liquid biopsy, NGS/multiomics sample preparation, single-cell spatial sequencing, and targeted drug and cell therapy. Its products are used by researchers at more than 40 institutions worldwide.